United States, California, Los Angeles - 07/27/2020 — CoNexus Cancer Centers Now Treating “No-Option” Stage III and IV Pancreatic Cancer Tumor Patients
Greg DiRienzo, CEO of CoNexus Cancer Centers America (www.conexuscancercenters.com) presents clinical study published in the Journal of Liver Research, Disorders and Therapy, wherein intratumoral (tumor-targeted) immunotherapy was shown to shrink and/or destroy late stage pancreatic tumors, without surgery, within weeks of starting treatment!
Pancreatic cancer remains one of the most malignant and aggressive cancers in the world (6% 5-yr survival rate with median survival of 6-9 months). Vital organ metastases (e.g. liver) by pancreatic cancer cells is very common, often preventing surgical resections. According to the study, a tumor-targeted immunotherapy protocol could lead to fewer patients requiring surgical removal of a pancreatic cancer tumor.
According to DiRienzo “in addition to non-surgical tumor destruction (debulking) tumor-targeted immunotherapy also showed favorable response to reducing tumor toxicity and hampering tumor growth, thus clearing potential microscopic cancer cells from spreading to surrounding tissues.”
CoNexus Cancer Care’s tumor-targeted, immunotherapy protocol is designed with the potential to serve three vital functions.
CoNexus Cancer Centers are located within greater Southern California and Baja California, Mexico, each providing highly trained and board-certified physicians committed to employ safe and effective therapies formulated to destroy cancerous tumors without compromising patient’s quality of life. CoNexus Cancer Center physicians have practiced in multiple international settings, including China, Canada, Germany, United States, Cuba, South Korea, and Mexico.
CONEXUS CANCER CENTERS AMERICA
Los Angeles, CA
Media Contacts:Company Name: Conexus Cancer Centers America